Proprietary Transdermal PlatformMedrx’s core focus on proprietary transdermal (patch) formulations and technologies is a durable competitive asset. Specialized formulation and patch manufacturing create high technical barriers, support licensing and supply contracts, and enable recurring partner revenue streams that can persist as the company scales.

Very High Gross MarginsSustained gross margins near 85–90% indicate attractive unit economics from the transdermal business. High gross profit per unit gives flexibility to cover R&D and SG&A, supports profitable licensing or contract-manufacturing models long-term, and improves upside when sales scale.

Conservative Capital Structure (no Debt)Zero reported debt through 2025 materially reduces solvency and interest-rate risk, preserving optionality for partnerships or equity raises. With no fixed interest burden, management can prioritize product development and strategic deals without near-term refinancing pressure.

Bears Say

Deep And Worsening Net LossesDespite revenue rebound, net losses expanded sharply in 2025 and margins deteriorated dramatically, indicating operating expenses and non-operating items far exceed revenues. Persistently large losses erode equity and require sustained external funding, limiting long-term financial stability.

Persistent Negative Operating And Free Cash FlowConsistent negative OCF and FCF show the business does not self-fund its operations or investments. Reliance on outside financing or equity issuance to cover cash burn can dilute shareholders, constrain R&D and commercialization capacity, and limit the firm's ability to execute long-term plans.

Negative ROE And Shareholder-value Erosion RiskPersistently negative ROE across multiple years signals the equity base is not generating returns and will decline if losses continue. Structural negative profitability undermines shareholder value, weakens negotiating power with partners, and raises the probability of dilutive financing over time.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥55.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥7.42B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 62 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.6.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 59,365,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥2.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.885%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.